Delcath Systems, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
24661P807
SEDOL
N/A
CIK
0000872912
www.delcath.com
LEI:
FIGI: BBG000BY2VF5
DCTH
Delcath Systems, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Delcath Systems, Inc.
ISIN
US24661P8077
TICKER
DCTH
MIC
XNAS
REUTERS
DCTH.OQ
BLOOMBERG
DCTH US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 03.01.2025
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual w...
Delcath Systems
Mo., 30.12.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to ...
Delcath Systems
Mo., 02.12.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in c...
Delcath Systems
Fr., 08.11.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024.
Third Quarter and Recent Business Highlights
Total third quarter r...
Delcath Systems
Fr., 01.11.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences:
Stephens Biotechnology Virtual Fireside Chats
Date: Wednesday, November 13, 2024
Fireside Chat Time: 9:30 a...
Delcath Systems
Fr., 25.10.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024.
Conference Call Information
To participate...
Delcath Systems
Do., 17.10.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the com...
Delcath Systems
Fr., 20.09.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted three equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of three indiv...
Delcath Systems
Mo., 16.09.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System (HDS)) in patients with metastatic uveal melanoma (mUM). The data were presented by Dr. M...
Delcath Systems
Mi., 28.08.2024
Delcath Systems
US24661P8077
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, entitled “Melanoma-specific survival of patients...
Delcath Systems
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
